The company’s decision to focus exclusively on medical cannabis serves as the foundation for its revised outlook. By integrating the recently acquired Safari Flower, Aurora aims to secure the necessary supply chain capacity to meet mounting pressure in Europe. Leadership noted that performance in Germany and Poland remains a primary driver for its positive earnings expectations, while a broader expansion into the United Kingdom is already moving through the execution phase.

Despite the ongoing friction with Curaleaf—which Aurora’s board dismissed as inadequate earlier this month—the firm intends to prioritize aggressive capital deployment. Plans to sustain investment in international operations over the coming quarters signal a long-term strategy to consolidate its footprint in medical-only markets rather than pivoting toward domestic recreational saturation.